Ga-PentixaFor

Phase 3Small molecule

NNantes University Hospital

Ga-PentixaFor is one of 92 small molecule programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

HyperaldosteronismActive, not recruiting

Multiple MyelomaActive, not recruiting

Small Cell Lung CancerActive, not recruiting

LymphomaPhase 3

Active, not recruiting

HyperaldosteronismPhase 2

Active, not recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Small Cell Lung CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Ga-PentixaFor

NNantes University Hospital

Phase 3

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Oncaspar

SServier

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Tafasitamab

Incyte

Preclinical

7 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

Nuvigil

NNuvo Research GmbH

Preclinical

1 9

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

N/ARecruiting

Multiple Myeloma

NCT06871176

Q2 2028

Phase 2Recruiting

Hyperaldosteronism

NCT06246357

Q3 2029

Phase 1Not yet recruiting

Small Cell Lung Cancer

NCT07007325

Q2 2030

Phase 2Recruiting

Multiple Myeloma

NCT04561492

Clinical

Trials by Indication[1]

Multiple Myeloma3 trials

PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)

Recruiting·UUniversity Health Network, Toronto·N/A·NCT06871176·30 enrolled

Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma

Recruiting·NNantes University Hospital·Phase 2·NCT04561492·45 enrolled

Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.

Withdrawn·NNantes University Hospital·Phase 2·NCT05321862

Lymphoma1 trial

[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma

Terminated·PPentixapharm AG·Phase 3·NCT06125028·13 enrolled

Small Cell Lung Cancer1 trial

Prospective Feasibility Pilot Study Evaluating the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small Cell Lung Cancer (SCLC) at Diagnosis and Disease Progression

Not yet recruiting·IInstitut Cancerologie de l'Ouest·Phase 1·NCT07007325·15 enrolled

Hyperaldosteronism1 trial

Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06246357·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Ga-PentixaFor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ga-PentixaFor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ga-PentixaFor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nantes University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNantes University Hospital

Ga-PentixaFor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2028

Q3 2029

Q2 2030

Trials by Indication[1]

Multiple Myeloma3 trials

Lymphoma1 trial

Small Cell Lung Cancer1 trial

Hyperaldosteronism1 trial

References

Drug Info

Quick Facts

Related News